VIVUS LLC has launched QSYMIA in the UAE, marking it as the first Middle Eastern approval for this obesity treatment. This initiative aligns with efforts to reduce obesity costs estimated at nearly $12 billion annually, providing significant advancements in patient care. The World Obesity Federation warns that around 7.5 million UAE residents may face obesity by 2035, underscoring the urgency of this public health crisis.
VIVUS LLC has officially launched QSYMIA® in the United Arab Emirates (UAE), marking a significant advancement in weight management as it becomes the first country in the Middle East to offer this treatment. QSYMIA is an extended-release combination of phentermine and topiramate, indicated for adults and pediatric patients ages twelve and older struggling with obesity. This development is pivotal for addressing the rising obesity epidemic, which costs the UAE nearly $12 billion annually.
This initiative is in collaboration with PharmaAccess, aiming to expand treatment options for healthcare professionals combating obesity in alignment with the UAE’s strategy against this growing health concern. Alphamed Drug Store will exclusively distribute QSYMIA within the UAE market. VIVUS expresses its dedication to addressing the obesity crisis globally through increased access to impactful therapies.
According to the World Obesity Federation, around 7.5 million individuals in the UAE are projected to face obesity by 2035, highlighting the urgent need for effective weight management solutions. The introduction of QSYMIA is anticipated to mitigate health risks associated with obesity and alleviate related economic burdens in the region. VIVUS is committed to providing sustainable weight management solutions to improve patient outcomes.
Globally, obesity is expected to impact one billion individuals by 2030, necessitating urgent action. VIVUS aims to extend QSYMIA availability to numerous European countries under the name QSIVA®, intending to reach over one billion people with access to this treatment by the end of 2025. The use of QSYMIA, in conjunction with a reduced-calorie diet and exercise, has demonstrated efficacy in assisting weight loss and maintenance in both adults and adolescents aged twelve and older.
QSYMIA is only for those who can manage its use alongside lifestyle changes; it is not suitable for everyone, especially during pregnancy or for those with certain medical conditions. Common side effects include paraesthesia, dizziness, and alterations in taste, while serious side effects may include birth defects and increased heart rate. Safety and effectiveness have not been established when combined with other weight loss products.
As for QSIVA, it carries similar contraindications and safety concerns as QSYMIA. Pregnant individuals or those who might become pregnant are strongly advised against using QSIVA due to potential fetal harm. Both medications require careful patient monitoring, especially among vulnerable populations such as children and adolescents.
VIVUS emphasizes its mission of offering innovative weight management therapies, underscoring its commitment to addressing obesity on a global scale. For further inquiries and detailed information on QSYMIA and QSIVA, stakeholders are encouraged to reach out to VIVUS or visit the respective product websites.
The launch of QSYMIA in the UAE signifies a critical step in combating obesity within the region, offering new treatment options that align with national health objectives. By expanding access to effective therapies, VIVUS aims to make a meaningful impact on public health and patient care. As the obesity epidemic continues to grow, innovative solutions like QSYMIA are essential in addressing both the health and economic challenges posed by this condition.
Original Source: www.globenewswire.com
